Heska Corporation, a provider of advanced veterinary diagnostic and specialty products, plans to report its fourth quarter and full year 2019 financial performance in a press release on Tuesday, February 25, 2020 before the market opens, and to host an earnings call to discuss the results following the release at 9 a.m. MT / 11 a.m. ET..
LOVELAND, Colo., Feb. 4, 2020 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; “Heska” or the “Company”), a provider of advanced veterinary diagnostic and specialty products, plans to report its fourth quarter and full year 2019 financial performance in a press release on Tuesday, February 25, 2020 before the market opens, and to host an earnings call to discuss the results following the release at 9 a.m. MT / 11 a.m. ET.
To access the conference call:
From within the United States, please dial 1-888-259-8389
From outside of the United States, please dial 1-323-794-2570
Reference Conference ID: 6976509
The earnings call will be webcast live from the Company’s website at https://ir.heska.com/.
A telephonic replay will be available beginning at 2 p.m. ET February 25 and will continue through 11:59 p.m. ET on Tuesday, March 10, 2020. The webcast will be archived on www.heska.com for 90 days.
To access the replay:
From within the United States, please dial 1-844-512-2921
From outside the United States, please dial 1-412-317-6671
Reference Replay Pin Number: 6976509
About Heska
Heska Corporation (NASDAQ: HSKA) manufactures, develops and sells advanced veterinary diagnostic and specialty healthcare products through two business segments. The Core Companion Animal Health (“CCA”) segment represents approximately 85% of revenues, and the Other Vaccines and Pharmaceuticals (“OVP”) segment represents approximately 15% of revenues, as of September 30, 2019. CCA segment includes Point of Care Laboratory testing instruments and consumables, primarily under a unique multi-year Reset Subscription model, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings such as in-clinic diagnostic tests and heartworm preventive products. OVP segment includes private label vaccine and pharmaceutical production under third party agreements and channels, primarily for herd animal health.
View original content to download multimedia:http://www.prnewswire.com/news-releases/heska-corporation-fourth-quarter-and-full-year-2019-financial-results-and-earnings-call-scheduled-for-february-25-2020-300998163.html
SOURCE Heska Corporation
Company Codes: NASDAQ-SMALL:HSKA
